Navigation Links
Perrigo Announces Approval for Rx Cetirizine Syrup
Date:6/19/2008

ALLEGAN, Mich., June 19 /PRNewswire-FirstCall/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has received final approval from the U.S. Food and Drug Administration to manufacture and market Cetirizine Hydrochloride Syrup (Rx only), 1mg/mL. The product is comparable to McNeil Consumer Healthcare's Zyrtec(R) Syrup, 1mg/mL, indicated for the relief of symptoms associated with seasonal allergic rhinitis.

Perrigo's Chairman and CEO Joseph C. Papa stated, "This approval reflects both our strategy to be first to market with important products and the unique position of the Company both in front of and behind the pharmacy counter. This product will join our line of Cetirizine tablets, Cetirizine D and Cetirizine OTC syrup. Additionally, it contains active ingredient supplied by our own API business, a continuation of our vertical integration efforts. This is yet another example of how we are making quality healthcare more affordable for consumers."

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and consumer products. The Company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. The Company's primary markets and locations of manufacturing facilities are the United States, Israel, Mexico and the United Kingdom. Visit Perrigo on the Internet (http://www.perrigo.com).

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 30, 2007, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Perrigo Company
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Perrigo Confirms Filing for Generic Version of VANOS(R)
2. Perrigo Company Announces Collaborative Agreement for Generic Topical Products With Pentech
3. Perrigo Company to Present at the Citi Investment Research Global Health Care Conference
4. Perrigo Reports Record Sales and Earnings for Third Quarter Fiscal 2008
5. Perrigo Company Announces Quarterly Dividend
6. Perrigo Receives FDA Approval to Market Orange, Coated Nicotine Gum
7. Perrigo Company Will Release Third Quarter Fiscal 2008 Results on May 6, 2008
8. Perrigo Confirms Patent Challenge of Monistat(R) 1 Combination Pack
9. Perrigo Company to Present at the 12th Annual Sidoti Emerging Growth Institutional Investor Forum
10. Perrigo Company Announces Launch of Clobetasol Propionate Foam
11. Perrigo Company Receives Final Approval on Clobetasol Propionate Foam
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... ... September 21, 2017 , ... The New England Center for ... today the election of Yie-Hsin Hung to the Board of Directors. , “The ... of Directors. Ms. Hung is an invaluable addition to our team,” said Vincent Strully, ...
(Date:9/21/2017)... ... September 21, 2017 , ... Sagora Senior Living, one of ... Kingwood Assisted Living and Memory Care located at 24025 Kingwood Place Drive, Kingwood, ... living apartments, 43 memory care apartments and 23 extended care apartments. Modern floor ...
(Date:9/20/2017)... ... 2017 , ... Collins Concrete Coatings announced that they offer ... safety and cleanliness. This unique flooring system uses silver ion technology to resist ... for its antimicrobial properties. Unlike antibiotics, which kill specific microorganisms, silver ions attack ...
(Date:9/20/2017)... ... 20, 2017 , ... Mirror Mirror Beauty Boutique is excited ... This Autumn with CoolSculpting®. Scheduled for Thursday, September 28th, the afternoon will include ... Beauty Boutique is Houston’s largest CoolSculpting provider, holding the prestigious title ...
(Date:9/20/2017)... ... September 20, 2017 , ... Each ... for the National Athletic Trainers’ Association Annual Clinical Symposium and Expo. New research ... is also when Athletic Trainers are acknowledged by their peers with accolades and ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... NeuroRx, a clinical stage biopharma company developing the first oral ... granted Fast Track status by the US Food and Drug ... by NRX-101 (D-cycloserine + lurasidone). The company will shortly begin ... targeting patients who are admitted to Emergency Departments with ASIB ... ...
(Date:9/5/2017)... Sept. 5, 2017 Sapheneia and Scannerside received ... Scannerside DoseCheck is a third-party Vendor neutral CT product ... and allows compliance with current MITA standards. ... 29 DoseCheck solution is specifically designed to provide CT ... potential radiation doses over a predefined threshold. Scannerside Dose ...
(Date:9/5/2017)... WAYNE, N.J. , Sept. 5, 2017 /PRNewswire/ ... technology, has created a vibrant charitable donation program ... funds and support congenital heart defect research by ... healthcare providers and the general public are encouraged ... and submit the completed artwork to the ...
Breaking Medicine Technology: